9 May 2017 (Tuesday) - The Oncologist Newsletter
"The Oncologist" email arrived in my in-box this morning:
Nadeem Tanveer
The success
of human papilloma virus (HPV) screening is attributable to clear-cut
guidelines on the detection and management of premalignant HPV lesions. A
similar approach is necessary for both low-risk and high-risk lesions,
including anogenital warts.
Precision Medicine Clinic
Enrico Castellucci, Tianfang He, D. Yitzchak Goldstein, Balazs Halmos, Jennifer Chuy
Two cases of
metastatic colorectal cancer with a POLE mutation, both of which were
ultramutated and microsatellite stable, are presented and discussed from
the standpoint of the basic biochemical mechanisms leading to a unique
phenotype in POLE deficiency, the challenges faced with interpreting the
genomic profiling of tumors in this important subset of patients, and
the potential clinical implications.
Clinical Trial Results
Xiao X. Wei, Andrew C. Hsieh, Won Kim, Terence Friedlander, Amy M. Lin, Mirela Louttit, Charles J. Ryan
Thomas S. Uldrick,
Priscila H. Gonçalves, Kathleen M. Wyvill, Cody J. Peer, Wendy
Bernstein, Karen Aleman, Mark N. Polizzotto, David Venzon, Seth M.
Steinberg, Vickie Marshall, Denise Whitby, Richard F. Little, John J.
Wright, Michelle A. Rudek, William D. Figg, Robert Yarchoan
Breast Cancer
Virginia G. Kaklamani, William J. Gradishar
Endocrine
therapy is an integral component of systemic therapy for metastatic
breast cancer. In addition, targeted therapies are emerging as useful
treatments. This article reviews current endocrine treatments of
metastatic breast cancer, as well as studies of combination treatments
and targeted therapies that interfere with cellular proliferation
pathways, as a means of overcoming resistance.
Filipa Lynce, Ana Barac, Ming T. Tan, Federico M. Asch, Karen L. Smith, Chau Dang, Claudine Isaacs, Sandra M. Swain
The
SAFE-HEaRt study tests the hypothesis that HER2 targeted therapies may
be safely used in patients with mildly decreased left ventricular
ejection fraction with appropriate cardiac monitoring and treatment.
This is the first prospective evaluation of HER2 targeted therapy in
patients with HER2 positive breast cancer and decreased cardiac
function, a group of patients who at present have limited treatment
options and therefore are at risk for worse oncologic outcomes.
Suyun Chen, Nuhad K. Ibrahim, Yuanqing Yan, Stephen T. Wong, Hui Wang, Franklin C. Wong
The objective of this study was to determine the prognostic role of complete metabolic response on 18F-fluorodeoxyglucose (18F-FDG)
positron emission tomography/computed tomography during or following
neoadjuvant chemotherapy in breast cancer patients. The association
between 18F-FDG metabolic parameters (including uptake) and survival outcome, according to breast cancer subtype, was investigated
Chelsea Anderson, Anne Marie Meyer, Stephanie B. Wheeler, Lei Zhou, Katherine E. Reeder-Hayes, Hazel B. Nichols
Ductal
carcinoma in situ accounts for over 20% of all breast cancer diagnoses.
The purpose of this study was to evaluate characteristics associated
with endocrine therapy initiation in the year after a diagnosis of
ductal carcinoma in situ and to investigate factors associated with
receiving medical oncology consultation among women with ductal
carcinoma in situ.
Cancer Biology
Marshall A. Lichtman
The history
of the discovery of microbes that increase the risk of cancer of some
tissues is reviewed, with a special emphasis on the discovery of the
bacterium Helicobacter pylori and its capability to induce two gastric
neoplasms: carcinoma and lymphoma.
Hematologic Malignancies
Hun Ju Lee, Jorge E.
Romaguera, Lei Feng, Aakash P. Desai, Liang Zhang, Michelle Fanale,
Felipe Samaniego, Fredrick B. Hagemeister, Luis E. Fayad, Maria A.
Rodriguez, Jeffrey L. Medeiros, Kimberly Hartig, Krystle Nomie, Makhdum
Ahmed, Maria Badillo, Haige Ye, Yasuhiro Oki, Pei Lin, Loretta
Nastoupil, Jason Westin, Michael Wang
Relapsed or
refractory mantle cell lymphoma has a poor prognosis. This article
presents the result of a phase II trial of the combination regimen of
rituximab, bortezomib, and cyclophosphamide in patients with relapsed or
refractory aggressive mantle cell lymphoma.
Katsuhiro Miura, Jun
Konishi, Takaaki Miyake, Masanori Makita, Atsuko Hojo, Yasufumi Masaki,
Masatoshi Uno, Jun Ozaki, Chikamasa Yoshida, Daigo Niiy, Koichi
Kitazume, Yoshinobu Maeda, Jun Takizawa, Rika Sakai, Tomofumi Yano,
Kazuhiko Yamamoto, Kazutaka Sunami, Yasushi Hiramatsu, Kazutoshi Aoyama,
Hideki Tsujimura, Jun Murakami, Yoshihiro Hatta, Masatoshi Kanno
R-CHOP has
improved the clinical outcome of diffuse large B-cell lymphoma compared
with CHOP alone; however, patients with unfavorable prognostic factors
have less change of benefitting from such standard treatments. Advanced
age is a crucial risk factor for unfavorable prognosis, as is
hypoalbuminemia and medical comorbidities. This study measured the
effects of these three biomarkers on clinical outcomes and developed a
decision-making treatment model that can serve as a guide for optimal
personalized therapy for elderly patients treated with R-CHOP.
Hepatobiliary
Yi-Peng Fu, Yong Yi,
Jin-Long Huang, Chu-Yu Jing, Jian Sun, Xiao-Chun Ni, Zhu-Feng Lu, Ya
Cao, Jian Zhou, Jia Fan, Shuang-Jian Qiu
This study
aimed to identify prognostic factors of patients with hepatocellular
carcinoma without portal vein tumor thrombosis and to establish
prognostic nomograms for recurrence-free survival and overall survival.
The accuracy of these nomograms for predicting individual prognosis is
compared with the accuracy of established clinical prognostic models to
ascertain whether the nomograms are an accurate instrument of prognosis
Neuro-Oncology
Marco Skardelly, Elena
Dangel, Julia Gohde, Susan Noell, Felix Behling, Guilherme Lepski,
Christian Borchers, Marilin Koch, Jens Schittenhelm, Sotirios Bisdas,
Aline Naumann, Frank Paulsen, Daniel Zips, Ulrike von Hehn, Rainer Ritz,
Marcos Soares Tatagiba, Ghazaleh Tabatabai
In clinical
practice, many centers continue temozolomide maintenance chemotherapy
beyond six cycles, a practice that is controversial. This study
investigated the effect of prolonged temozolomide maintenance therapy on
progression-free survival and overall survival in newly diagnosed
glioblastoma.
New Drug Development and Clinical Pharmacology
Mina Nikanjam, Sariah Liu, Jincheng Yang, Razelle Kurzrock
This study
aimed to determine the lowest safe starting doses observed in previously
published phase I, II, and III adult oncology clinical protocols to
help avoid excessive toxicity when dosing of de novo three-drug
combinations involving a targeted agent in clinical trials and practice.
Regulatory Issues: FDA
Yvette L. Kasamon, R. Angelo de Claro, Yaping Wang, Yuan Li Shen, Ann T. Farrell, Richard Pazdur
On May 17,
2016, after an expedited priority review, the U.S. Food and Drug
Administration granted accelerated approval for nivolumab for the
treatment of patients with classical Hodgkin L that has relapsed or
progressed after autologous HSCT and post-transplantation brentuximab
vedotin. This was the first FDA application for a PD-1 inhibitor in
hematologic malignancies. A summary of the FDA review and approval is
presented here.
Symptom Management and Supportive Care
Michio Nakamura,
Atsushi Ishiguro, Tetsuhito Muranaka, Hiraku Fukushima, Satoshi Yuki,
Kota Ono, Taichi Murai, Chika Matsuda, Ayane Oba, Kazufumi Itaya,
Takayuki Sone, Masataka Yagisawa, Yuta Koike, Ayana Endo, Yoko Tsukuda,
Yuji Ono, Takahiko Kudo, Atsushi Nagasaka, Shuji Nishikawa, Yoshito
Komatsu
This study is
an evaluation of the effect of gastrointestinal cancer chemotherapy
with short-term periodic steroid premedication on bone metabolism.
Primary endpoints were changes in bone mineral densities and metabolic
bone turnover 16 weeks after initiation of chemotherapy.
Chiara Alessandra
Cella, Giovanni Di Minno, Chiara Carlomagno, Michele Arcopinto, Anna
Maria Cerbone, Elide Matano, Antonella Tufano, Florian Lordick, Biagio
De Simone, Katja Sibylle Muehlberg, Dario Bruzzese, Laura Attademo,
Claudia Arturo, Marta Sodano, Roberto Moretto, Ersilia La Fata, Sabino
De Placido
Stratification
of risk through predictive models is a strategic method for reducing
the burden of venous thromboembolism in cancer patients. The objective
of this study was to derivate a novel predictive scoring tool for
measuring the risk of the individual patient.
Daniel J. Crona, Aimee Faso, Tomohiro F. Nishijima, Kathleen A. Mcgraw, Matthew D. Galsky, Matthew I. Milowsky
Various
hydration regimens and supplementation strategies are used to prevent
cisplatin-induced kidney injury; however, evidence-based recommendations
on specific hydration regimens are limited. This systematic review of
the literature evaluates clinical studies that have examined hydration
and supplementation strategies to prevent cisplatin-induced
nephrotoxicity.
Brief Communications
Vivek Narayan, Charuhas Deshpande, Christian A. Bermudez, Jaclyn M. Golato, James C. Lee, Joshua Diamond, David J. Vaughn
Lung injury
is the most severe complication of bleomycin chemotherapy. In patients
with advanced germ cell tumor receiving bleomycin therapy, there is risk
of severe bleomycin-induced pulmonary toxicity. The case reported here
is the first to show that lung transplantation can be successfully used
for severe bleomycin-related lung injury.
Michael Karass, Emily Grossniklaus, Talal Seoud, Sanjay Jain, Daniel A. Goldstein
A case of
Kaposi sarcoma inflammatory cytokine syndrome is presented and available
literature reviewed. New treatment modalities to manage this condition
are also discussed.
Narratives in Oncology
Tania Echeveste
An oncologist training in Mexico reflects on her journey as a fellow and the patient who changed her life.
![The Oncologist Footer]()
No comments:
Post a Comment